Analyst firms · Raymond James · BSX
Raymond James BSX price target and rating history
Boston Scientific Corporation (BSX) · Health Care
Raymond James rates Boston Scientific Corporation (BSX) Outperform with a $88 price target, as of its latest action on Mar 30, 2026. It has published 4 rating actions on BSX since July 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a BSX price target in the last 12 months, the median target is $50. Raymond James's $88 is 76% above that.
- Current rating
- Outperform
- Price target
- $88
- Median target, all firms
- $50
- Actions on BSX
- 4
Raymond James price target on BSX
Every Raymond James rating on BSX
- Mar 30, 2026
- Feb 3, 2022
- Oct 28, 2021
- Jul 28, 2021
How other firms rate BSX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| TD Cowen | Hold | $46 | Oct 30, 2026 |
| Oppenheimer | Perform | Oct 29, 2026 | |
| Barclays | Equal Weight | $48 | Oct 7, 2026 |
| Citigroup | Neutral | $50 | Sep 17, 2026 |
| Argus Research | Hold | Jul 31, 2026 | |
| Wolfe Research | Peer Perform | May 29, 2026 | |
| Wells Fargo | Equal Weight | $55 | May 28, 2026 |
| Raymond James | Outperform | $88 | Mar 30, 2026 |
Questions about Raymond James and BSX
- What is Raymond James's price target for BSX?
- Raymond James's latest stated price target for Boston Scientific Corporation (BSX) is $88, from its action on Mar 30, 2026.
- What is Raymond James's rating on BSX?
- Raymond James rates BSX Outperform, a bullish rating, as of Mar 30, 2026.
- When did Raymond James last change its view on BSX?
- On Mar 30, 2026, Raymond James downgrades to Outperform from Strong Buy, price target $88.
- How does Raymond James's BSX target compare with other analysts?
- Across 5 firms with a BSX price target in the last 12 months, the median target is $50. Raymond James's $88 is 76% above that.
More BSX rating histories
All Raymond James ratingsBSX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.